氯喹与人血浆蛋白结合的特性研究。
Characterization of chloroquine plasma protein binding in man.
作者信息
Walker O, Birkett D J, Alván G, Gustafsson L L, Sjöqvist F
出版信息
Br J Clin Pharmacol. 1983 Mar;15(3):375-7. doi: 10.1111/j.1365-2125.1983.tb01513.x.
Abstract
Chloroquine protein binding was determined by equilibrium dialysis of purified plasma proteins and plasma samples from 20 healthy subjects and 14 patients with rheumatoid arthritis. The mean binding was 61 +/- 9% in plasma from healthy subjects (range 46-74%) and 64 +/- 7% in plasma from rheumatoid arthritis patients (range 55-79%). Albumin and alpha 1-acid glycoprotein at physiological concentrations bound chloroquine to an approximately equal extent. Protein binding is unlikely to be an important determinant of chloroquine pharmacokinetics or response.
摘要
通过对20名健康受试者和14名类风湿性关节炎患者的纯化血浆蛋白及血浆样本进行平衡透析，测定了氯喹的蛋白结合情况。健康受试者血浆中的平均结合率为61±9%（范围46 - 74%），类风湿性关节炎患者血浆中的平均结合率为64±7%（范围55 - 79%）。生理浓度下的白蛋白和α1 - 酸性糖蛋白对氯喹的结合程度大致相等。蛋白结合不太可能是氯喹药代动力学或反应的重要决定因素。
相似文献
1
Characterization of chloroquine plasma protein binding in man.氯喹与人血浆蛋白结合的特性研究。
Br J Clin Pharmacol. 1983 Mar;15(3):375-7. doi: 10.1111/j.1365-2125.1983.tb01513.x.
2
Protein binding of chloroquine enantiomers and desethylchloroquine.氯喹对映体和去乙基氯喹的蛋白结合
Br J Clin Pharmacol. 1986 Sep;22(3):356-8. doi: 10.1111/j.1365-2125.1986.tb02900.x.
3
Chloroquine treatment in rheumatoid arthritis. Correlation of clinical response to plasma protein changes and chloroquine levels.
Scand J Rheumatol. 1978;7(3):171-6. doi: 10.3109/03009747809095649.
4
Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis.类风湿关节炎患者长期治疗期间血液中的氯喹水平
Eur J Clin Pharmacol. 1992;42(4):429-33. doi: 10.1007/BF00280130.
5
Pharmacokinetics of chloroquine in renal insufficiency.氯喹在肾功能不全患者中的药代动力学。
Afr J Med Med Sci. 1984 Sep-Dec;13(3-4):177-82.
6
[Serum concentrations and side effects in rheumatoid patient treated with chloroquine].[氯喹治疗类风湿关节炎患者的血清浓度及副作用]
Lakartidningen. 1979 Feb 28;76(9):725-6.
7
Pharmacokinetics of chloroquine: saliva and plasma levels relationship.氯喹的药代动力学：唾液与血浆水平的关系。
Eur J Drug Metab Pharmacokinet. 1986 Oct-Dec;11(4):275-81. doi: 10.1007/BF03189112.
8
Pharmacokinetic interactions of penicillamine in rheumatoid arthritis.
J Rheumatol. 1989 Apr;16(4):473-4.
9
[Amino acid composition of the components of the resochin test under normal conditions and in rheumatoid arthritis].[正常条件及类风湿性关节炎情况下雷琐辛试验各成分的氨基酸组成]
Revmatologiia (Mosk). 1985 Apr-Jun(2):39-42.
10
[Protein binding of salicylates in rheumatoid arthritis].[类风湿关节炎中水杨酸盐的蛋白结合]
Rev Rhum Mal Osteoartic. 1982 May;49(6):447-52.
引用本文的文献
1
Biologic Functions of Hydroxychloroquine in Disease: From COVID-19 to Cancer.羟氯喹在疾病中的生物学功能：从新冠病毒疾病到癌症
Pharmaceutics. 2022 Nov 22;14(12):2551. doi: 10.3390/pharmaceutics14122551.
2
Drug-induced self-assembled nanovesicles for doxorubicin resistance reversal via autophagy inhibition and delivery synchronism.药物诱导的自组装纳米囊泡通过自噬抑制和递送同步逆转多柔比星耐药性。
Theranostics. 2022 May 13;12(8):3977-3994. doi: 10.7150/thno.70852. eCollection 2022.
3
Biomimetic properties and estimated in vivo distribution of chloroquine and hydroxy-chloroquine enantiomers.氯喹和羟基氯喹对映体的仿生特性及体内分布估计
ADMET DMPK. 2020 Jan 25;9(2):151-165. doi: 10.5599/admet.929. eCollection 2021.
4
Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.羟氯喹在系统性红斑狼疮中的应用：当前知识概述
Ther Adv Musculoskelet Dis. 2022 Feb 14;14:1759720X211073001. doi: 10.1177/1759720X211073001. eCollection 2022.
5
Aminoquinolines as Translational Models for Drug Repurposing: Anticancer Adjuvant Properties and Toxicokinetic-Related Features.氨基喹啉类药物作为药物重新利用的转化模型：抗癌辅助特性及与毒代动力学相关的特征
J Oncol. 2021 Sep 3;2021:3569349. doi: 10.1155/2021/3569349. eCollection 2021.
6
Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.针对 SARS-CoV-2 主蛋白酶的选择性潜在抗病毒药物的分子对接、结合模式分析、分子动力学和 ADMET/毒性性质预测：药物再利用以对抗 COVID-19 的努力。
Mol Divers. 2021 Aug;25(3):1905-1927. doi: 10.1007/s11030-021-10188-5. Epub 2021 Feb 13.
7
Physiologically Based Pharmacokinetics of Lysosomotropic Chloroquine in Rat and Human.溶酶体靶向性氯喹在大鼠和人体中的生理药代动力学。
J Pharmacol Exp Ther. 2021 Feb;376(2):261-272. doi: 10.1124/jpet.120.000385. Epub 2020 Dec 4.
8
Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions.研究性 COVID-19 治疗方法可能通过药物相互作用增加室性心律失常风险。
CPT Pharmacometrics Syst Pharmacol. 2021 Feb;10(2):100-107. doi: 10.1002/psp4.12573. Epub 2021 Feb 11.
9
Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine.新冠疫情下药物的重新利用：氯喹和羟氯喹的药代动力学和药物基因组学
Pharmgenomics Pers Med. 2020 Oct 23;13:531-542. doi: 10.2147/PGPM.S275964. eCollection 2020.
10
Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.体外治疗氯喹、羟氯喹和奎宁中毒：来自 EXTRIP 工作组的系统评价和建议。
J Am Soc Nephrol. 2020 Oct;31(10):2475-2489. doi: 10.1681/ASN.2020050564. Epub 2020 Sep 22.
本文引用的文献
1
Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults.血浆蛋白药物结合的年龄差异：对人类胎儿、新生儿和成年人的研究。
Eur J Clin Pharmacol. 1971 Sep;3(4):189-93. doi: 10.1007/BF00565004.
2
Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.碱性药物的血浆蛋白结合。II. α1-酸性糖蛋白对个体间差异的重要性。
Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):545-9. doi: 10.1002/cpt1977225part1545.
3
The binding of chloroquine to normal and Kwashiorkor serum.氯喹与正常血清和夸休可尔症血清的结合
Am J Trop Med Hyg. 1977 Sep;26(5 Pt 1):1025-7. doi: 10.4269/ajtmh.1977.26.1025.
Zotero 插件